NCT04458298View on ClinicalTrials.gov

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
COVID-19
Interventions
DRUG

OP-101

OP-101 infusion will be administered intravenously.

DRUG

Placebo

Matching placebo infusion will be administered intravenously.

Trial Locations (8)

21287

Research site, Baltimore

30342

Research Site, Atlanta

32209

Research site, Jacksonville

33316

Research site, Fort Lauderdale

57105

Research Site, Sioux Falls

77030

Research Site, Houston

79109

Research Site, Amarillo

92354

Research Site, Loma Linda

Sponsors
All Listed Sponsors
lead

Ashvattha Therapeutics, Inc.

INDUSTRY

NCT04458298 - A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients | Biotech Hunter | Biotech Hunter